Correspondingly, the BRD4 inhibitor JQ1 has previouslybeen shown to reverse experimental PH in rodent models [179], and the BRD4inhibitor apabetalone (RVX208) is currently under Phase 2 clinical investigationin PAH (ClinicalTrials.gov identifier NCT04915300) [276, 277]. The gene discussed is BRD4; the disease is pulmonary arterial hypertension.